Antares Pharma, Inc.EBSCO_bspAntares Pharma Inc Swot Analysis
Antares Pharma Inc NSDAQ:ATRS 交易中 美东时间:7日 11:28:53 加入自选股 货币单位: 美元(USD) 退市 今开:0.00 最高价:0.00 52周最高价:0.00 成交量:0 昨收:5.59 最低价:0.00 52周最低价:0.00 市值:9.55亿 市盈率:24.30 每股收益:0.23 每股派息:-- 总股本:17085万股东...
ntares Pharma, Inc. Antares Pharma, Inc.Antares Pharma, Inc.EBSCO_bspAntares Pharma
EWING, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) --Antares Pharma, Inc., (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has initiated a Phase 1 study for ATRS-1902 for adrenal crisis rescue...
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc. Translations --- Select a language: Want to thank TFD for its existence?Tell a friend about us, add a link to this page, or visitthe webmaster's page for free fun content. Link to this...
RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook Dictionary Thesaurus Medical Encyclopedia Wikipedia AcronymDefinition ANTARESAstronomy with a Neutrino Telescope and Abyss Environmental Research ANTARESApplication des Nouvelles Technologies au Recrutement des Enseignants du Supér...
Pharmas Turn to Licensing Deals as Risky Science Rises Annalee Armstrong Opinion A Cautiously Sunny Outlook for Biopharma in 2025 Bryan Spielman MORE ON THIS TOPIC Gene therapy Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku ...
Create Free Account By creating an account using any of the options above, you agree to theTerms of Use&Privacy Policy ATRSAntares Pharma, Inc. Stock Price & Overview Follow ATRS is defunct since May 25, 2022. Defunct Summary Power to Investors ...
Antares Pharma Inc. (ATRS) $5.590.00(0.00%) September 16, 2022 4:00 PMEST USDNASDAQ Capital MarketDelayed PriceMarket Closed Earnings High Target Price 7.00 Mean Target Price 5.95 Low Target Price 5.60 Standard Deviation: 0.70 Number of Estimates 4 Date of Most Recent Estimate 04/14/22 Pric...
“Optimization of binary and ternary solvent systems in the percutaneous absorption of morphine base”, STP Pharma Sciences, 1991; 1: 71-75; Ritschel, W. A., Barkhaus, J K., “Use of absorption promoters to increase systemic absorption of coumarin from transdermal drug delivery systems”, ...